134:
Time for Baby"), a study that aims to evaluate the safety of interrupting endocrine therapy for young women with hormone-sensitive breast cancer who wish to become pregnant, as well as the pregnancy outcomes. Other research in this category includes AURORA (the "Metastatic Breast Cancer GPS"), EXPERT ("BIG Radio Tuning") and the
International Programme of Breast Cancer in Men. AURORA, for example, is an ambitious molecular screening programme aimed at understanding the aberrations driving breast cancer metastasis, understanding the evolution of the disease, and understanding why some tumours respond exceptionally well or very poorly to treatment.
25:
110:
several thousand specialised hospitals and research centres worldwide. More than 30 clinical trials and research programmes are run or are under development under the BIG umbrella at any one time, and several of BIG's past studies are already considered landmark and practice-changing. BIG also works closely with the US National Cancer
Institute (NCI) and the North American Breast Cancer Groups (NABCG), so that together they act as a strong integrating force in the breast cancer research arena.
278:
many areas of research that hold great promise for patients but have no particular interest for commercial partners. It is possible that many individual patients could be cured or otherwise benefit from a “lighter” exposure to traditional cancer treatments, for example by having the duration of their exposure to certain drugs or radiation reduced, or even eliminated altogether.
145:. These principles are designed to ensure that, while trials will meet industry requirements from a regulatory standpoint, BIG and its members remain responsible for determining the research agenda, for controlling the clinical study data, and for presenting and publishing research findings (positive and negative) according to academic standards. In this way,
118:
Over the years, BIG has developed and successfully run numerous large, phase 3 clinical trials involving thousands of international investigators and institutions. These clinical trials include HERA (HERceptin
Adjuvant), MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May
277:
The Breast
International Group’s purely academic research is supported in part by BIG against breast cancer, BIG’s the philanthropic unit. The funds raised by BIG against breast cancer go towards financing purely academic breast cancer trials and research conducted under the BIG umbrella. There are
133:
While many trials under the BIG umbrella are developed in collaboration with the pharmaceutical industry, BIG also designs and conducts purely academic studies, aiming to answer questions that are essential to patients but with no commercial interest. This is the case for POSITIVE (public name "BIG
268:
The assembly of member groups of the BIG network, known as the
General Assembly, acts as the association's governing body. It is the BIG organization's final decision-making body and also decides on proposals made by the Executive Board on subjects of crucial strategic and scientific relevance.
109:
They created BIG in 1996 and the group became a legal entity in 1999. Over 20 years later, BIG constitutes the largest global network dedicated solely to breast cancer. It unites 57 academic research groups based in Europe, Canada, Latin
America, Asia and Australasia. These entities are tied to
96:
BIG facilitates breast cancer research at an international level by stimulating cooperation between its members and other academic networks, and collaborating with, but working independently of, the pharmaceutical industry. Such large-scale cooperation is crucial to make significant advances in
105:
In the early 1990s, breast cancer research in Europe was highly fragmented, with academic groups running many similar trials, but not yet interacting in a way to facilitate collaboration. Together, Professors
Martine Piccart and the late Aron Goldhirsch, two European opinion leaders, shared a
126:
on the map (BIG 1-98), changing how we treat young women with breast cancer (SOFT), leading to a major breakthrough in treating HER2-positive breast cancer (HERA), or helping physicians evaluate which women with early breast cancer could be spared chemotherapy after surgery (MINDACT).
97:
breast cancer research, reduce the wasteful duplication of effort and resources, enrol numerous patients more quickly, share data and knowledge, and efficiently answer important scientific questions. Faster and robust study results mean faster direct benefits to patients.
137:
These academic studies are made possible only by the generous support of foundations, individual donors, ambassadors, companies and by the fundraising activities run by BIG's philanthropy unit, BIG against breast cancer.
157:
The executive board is responsible for BIG's overall direction. It meets frequently throughout the year to create BIG's scientific strategy, implement general assembly resolutions, and supervise the association.
130:
Most BIG trials incorporate a substantial translational research component and emphasise the collection and banking of biological specimens for the purpose of future research.
106:
different vision for the future: groups debating the latest research findings, sharing ideas for new clinical trials and working in harmony to conduct these trials together.
165:
is
Immediate Past Chair of the Group and President of BIG against breast cancer. BIG's Co-Founder and Past Vice-Chair Dr. Aron Goldhirsch passed away on 26 February 2020.
457:
452:
324:
287:
Piccart M, Goldhirsch A, Straehle C, The Breast
International Group - a new spirit of collaboration in breast cancer research for the new millennium, E
309:
336:
141:
It is important to note that all of BIG's research activities, whether undertaken with commercial or academic partners, adhere to
360:
301:
Gnant M, Piccart M, Goldhirsch A et al. Developing an international network for breast cancer research: the BIG experience,
447:
68:
46:
325:
https://bigagainstbreastcancer.org/wp-content/uploads/2022/09/BIG-01-VisionMissionPrinciplesResearchConduct-V3.0.pdf
39:
33:
405:
119:
Avoid
Chemotherapy), and ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation).
50:
361:"In memory of Aron Goldhirsch, challenging oncologist with a vision | Cancer World Magazine"
8:
123:
149:
while developing and conducting collaborative research with a variety of partners.
381:
162:
441:
86:
294:
Piccart M, Goldhirsch A, Wood W et al. Keeping faith with trial volunteers.
432:
228:
161:
The Breast International Group is now chaired by Dr. David Cameron (UK).
122:
Many BIG studies have been practice-changing, for example, putting
90:
89:
research groups from around the world, with its headquarters in
113:
291:, Volume 36, Number 14, September 2000, pp. 1733–1736(4)
310:
Hope and Progress - 20 years of breast cancer research
169:Currently sitting on the BIG executive board are:
458:Medical and health organisations based in Belgium
439:
453:International medical and health organizations
85:is a not-for-profit organisation for academic
337:"Professor David Cameron appointed BIG Chair"
272:
114:BIG clinical trials and research programmes
69:Learn how and when to remove this message
32:This article includes a list of general
440:
433:Breast International Group (BIG)-aisbl
147:BIG preserves its scientific integrity
83:Breast International Group (BIG)-aisbl
143:BIG's Principles of Research Conduct
18:
13:
308:Breast International Group (BIG),
38:it lacks sufficient corresponding
14:
469:
426:
23:
398:
374:
353:
329:
318:
1:
281:
152:
7:
448:Breast cancer organizations
406:"BIG against breast cancer"
341:The University of Edinburgh
10:
474:
410:Breast International Group
386:Breast International Group
215:Dr. Giuseppe Curigliano -
179:Dr. Ander Urruticoechea -
100:
16:International organisation
289:uropean Journal of Cancer
273:BIG against breast cancer
221:Dr. Barbro Linderholm -
261:Dr. Gustavo Werutsky -
53:more precise citations.
305:, (2011) 1(5), 623–628
303:Clinical Investigation
263:Executive Board Member
257:Executive Board Member
251:Executive Board Member
245:Executive Board Member
243:Dr. Evangelia Razis -
239:Executive Board Member
237:Dr. Seamus O’Reilly -
233:Executive Board Member
223:Executive Board Member
217:Executive Board Member
211:Executive Board Member
205:Executive Board Member
199:Executive Board Member
193:Executive Board Member
187:Executive Board Member
185:Dr. Philippe Bedard -
249:Dr. Shigehira Saji -
197:Prof. Judith Bliss -
255:Dr. Ines Vaz-Luis -
191:Dr. Etienne Brain -
173:Dr. David Cameron -
124:aromatase inhibitors
203:Dr. Eva Carrasco -
163:Dr. Martine Piccart
298:446:137-138, 2007
91:Brussels, Belgium
79:
78:
71:
465:
420:
419:
417:
416:
402:
396:
395:
393:
392:
378:
372:
371:
369:
368:
357:
351:
350:
348:
347:
333:
327:
322:
209:Dr. Boon Chua -
74:
67:
63:
60:
54:
49:this article by
40:inline citations
27:
26:
19:
473:
472:
468:
467:
466:
464:
463:
462:
438:
437:
429:
424:
423:
414:
412:
404:
403:
399:
390:
388:
380:
379:
375:
366:
364:
359:
358:
354:
345:
343:
335:
334:
330:
323:
319:
284:
275:
168:
155:
116:
103:
75:
64:
58:
55:
45:Please help to
44:
28:
24:
17:
12:
11:
5:
471:
461:
460:
455:
450:
436:
435:
428:
427:External links
425:
422:
421:
397:
373:
352:
328:
316:
315:
314:
313:
306:
299:
292:
283:
280:
274:
271:
266:
265:
259:
253:
247:
241:
235:
225:
219:
213:
207:
201:
195:
189:
183:
177:
154:
151:
115:
112:
102:
99:
77:
76:
31:
29:
22:
15:
9:
6:
4:
3:
2:
470:
459:
456:
454:
451:
449:
446:
445:
443:
434:
431:
430:
411:
407:
401:
387:
383:
377:
362:
356:
342:
338:
332:
326:
321:
317:
311:
307:
304:
300:
297:
293:
290:
286:
285:
279:
270:
264:
260:
258:
254:
252:
248:
246:
242:
240:
236:
234:
230:
226:
224:
220:
218:
214:
212:
208:
206:
202:
200:
196:
194:
190:
188:
184:
182:
178:
176:
172:
171:
170:
166:
164:
159:
150:
148:
144:
139:
135:
131:
128:
125:
120:
111:
107:
98:
94:
92:
88:
87:breast cancer
84:
73:
70:
62:
52:
48:
42:
41:
35:
30:
21:
20:
413:. Retrieved
409:
400:
389:. Retrieved
385:
382:"Governance"
376:
365:. Retrieved
363:. 2020-03-03
355:
344:. Retrieved
340:
331:
320:
302:
295:
288:
276:
267:
262:
256:
250:
244:
238:
232:
222:
216:
210:
204:
198:
192:
186:
180:
174:
167:
160:
156:
146:
142:
140:
136:
132:
129:
121:
117:
108:
104:
95:
82:
80:
65:
56:
37:
229:Sherene Loi
59:August 2010
51:introducing
442:Categories
415:2023-09-25
391:2023-09-25
367:2021-03-08
346:2021-03-08
282:References
153:Governance
34:references
181:Treasurer
101:History
47:improve
312:, 2019
296:Nature
36:, but
175:Chair
227:Dr.
81:The
444::
408:.
384:.
339:.
231:-
93:.
418:.
394:.
370:.
349:.
72:)
66:(
61:)
57:(
43:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.